TScan Therapeutics, Inc.TCRXNASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank33
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-1287.62%
Near historical average
Percentile
P33
Within normal range
Streak
1 yr
Consecutive growthExpanding
Average
-1301.99%
Historical baseline
PeriodValueYoY Change
TTM-1287.62%+69.7%
2024-4252.06%-1017.4%
2023-380.53%+14.0%
2022-442.62%+0.9%
2021-446.67%+80.6%
2020-2304.42%-
20190.00%-